#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Transplant rejection Urethral valves Extranodal marginal zone B-cell lymphoma (MALT type) Cholangiocarcinoma Depression Renal cancer metastatic Atypical haemolytic uraemic syndrome Anal cancer Peripheral T-cell lymphoma unspecified Pneumonia T-cell type acute leukaemia Marginal zone lymphoma Myxoid liposarcoma Cardiac amyloidosis Measles More trials…

    Learn about Rare Diseases

    Cerebral arteriovenous malformation haemorrhagic – Basic Information Haemophilia – Basic Information Ornithine transcarbamoylase deficiency – Diagnostics Combined immunodeficiency – Treatment Synovial sarcoma metastatic – Life with Disease Rhabdoid tumour – Life with Disease Soft tissue sarcoma – Trials in Disease Leiomyosarcoma – Basic Information Mantle cell lymphoma stage II – Treatment Acquired haemophilia – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dolutegravir Sodium Ribonucleic Acid K30 Dfv890 Vixarelimab Emibetuzumab Fludarabine Phosphate 177LU-FAP-2286 Kd050 Tianeptine Methadone Hydrochloride [89ZR]ZR-DFO-CIT-013 Doxazosin Mesilate Olodaterol Taletrectinib Donepezil Imipenem Monohydrate RIVASTIGMINE Doxycycline Hyclate Ab-729 Thymalfasin More therapies…

    Learn about Your Condition

    Laryngeal cancer stage I Migraine with aura Neck pain Medullary thyroid cancer Mantle cell lymphoma Glomerulonephritis acute Rhabdoid tumour of the kidney Polymyositis Pneumococcal infection Pain Pustular psoriasis Conjunctivitis Mucosal inflammation Infant sedation Pyoderma gangrenosum More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus…

Centrum für Hämatologie und Onkologie am Bethanien-Krankenhaus

Iv Pgsbvdcb 1osacl Fcsdtoryas 6myqjw Godheky

Want to learn more about this study or check if you can participate? Contact us.

  • Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Letrozole
    • Palbociclib
    France Germany Italy Poland Spain

  • Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Lenalidomide
    • Bortezomib
    • Daratumumab
    Germany

  • Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Belantamab Mafodotin
    • Bortezomib
    • Carfilzomib
    France Germany Greece The Netherlands Spain

  • Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Idelalisib
    • Bendamustine Hydrochloride
    • BGB-16673
    Czechia Germany Italy The Netherlands Poland

  • Study of Iberdomide and Isatuximab for Maintenance Therapy in Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Iberdomide
    • Isatuximab
    • Dexamethasone
    Austria Germany

  • Study of Sacituzumab Govitecan for Patients with Advanced or Metastatic Bladder Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell cancer of the renal pelvis and ureter
    Investigated Drugs:
    • Domvanalimab
    • Zimberelimab
    • Avelumab
    France Germany Greece Italy Spain

  • Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elacestrant
    • Ribociclib
    Austria Germany Spain

  • Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Palbociclib
    Austria Belgium Germany Hungary Ireland Italy +5

  • Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer stage I
    • Breast cancer female
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Cisplatin
    Austria Belgium France Germany Ireland Spain

  • Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Abemaciclib
    • Anastrozole
    • Exemestane
    Germany
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!